• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

针对原发性和复发性艰难梭菌病的牛抗体是一种有效的抗生素替代药物。

Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative.

机构信息

Infection and Immunity Program, Monash Biomedicine Discovery Institute and Department of Microbiology, Monash University, Clayton, Victoria, 3800, Australia.

出版信息

Sci Rep. 2017 Jun 16;7(1):3665. doi: 10.1038/s41598-017-03982-5.

DOI:10.1038/s41598-017-03982-5
PMID:28623367
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5473923/
Abstract

The increased incidence of antibiotic resistant 'superbugs' has amplified the use of broad spectrum antibiotics worldwide. An unintended consequence of antimicrobial treatment is disruption of the gastrointestinal microbiota, resulting in susceptibility to opportunistic pathogens, such as Clostridium difficile. Paradoxically, treatment of C. difficile infections (CDI) also involves antibiotic use, leaving patients susceptible to re-infection. This serious health threat has led to an urgent call for the development of new therapeutics to reduce or replace the use of antibiotics to treat bacterial infections. To address this need, we have developed colostrum-derived antibodies for the prevention and treatment of CDI. Pregnant cows were immunised to generate hyperimmune bovine colostrum (HBC) containing antibodies that target essential C. difficile virulence components, specifically, spores, vegetative cells and toxin B (TcdB). Mouse infection and relapse models were used to compare the capacity of HBC to prevent or treat primary CDI as well as prevent recurrence. Administration of TcdB-specific colostrum alone, or in combination with spore or vegetative cell-targeted colostrum, prevents and treats C. difficile disease in mice and reduces disease recurrence by 67%. C. difficile-specific colostrum should be re-considered as an immunotherapeutic for the prevention or treatment of primary or recurrent CDI.

摘要

广谱抗生素的广泛使用加剧了抗生素耐药“超级细菌”的发生。抗菌治疗的一个意外后果是破坏了胃肠道微生物群,导致易患机会性病原体,如艰难梭菌。具有讽刺意味的是,艰难梭菌感染(CDI)的治疗也涉及抗生素的使用,使患者容易再次感染。这一严重的健康威胁促使人们迫切需要开发新的疗法来减少或替代抗生素治疗细菌感染。为了满足这一需求,我们开发了源自牛初乳的抗体,用于预防和治疗 CDI。对怀孕的奶牛进行免疫接种,以产生含有针对艰难梭菌必需毒力成分的抗体的高免疫牛初乳(HBC),特别是孢子、营养细胞和毒素 B(TcdB)。我们使用小鼠感染和复发模型来比较 HBC 预防或治疗原发性 CDI 以及预防复发的能力。单独给予 TcdB 特异性牛初乳,或与靶向孢子或营养细胞的牛初乳联合使用,可预防和治疗小鼠的艰难梭菌疾病,并将疾病复发减少 67%。艰难梭菌特异性牛初乳应重新考虑作为预防或治疗原发性或复发性 CDI 的免疫疗法。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7db4/5473923/8f64f58fe3ad/41598_2017_3982_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7db4/5473923/160f10207810/41598_2017_3982_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7db4/5473923/7945c994fc74/41598_2017_3982_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7db4/5473923/274f2ea04534/41598_2017_3982_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7db4/5473923/a8ce585f0e19/41598_2017_3982_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7db4/5473923/c07e7515c9c6/41598_2017_3982_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7db4/5473923/8f64f58fe3ad/41598_2017_3982_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7db4/5473923/160f10207810/41598_2017_3982_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7db4/5473923/7945c994fc74/41598_2017_3982_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7db4/5473923/274f2ea04534/41598_2017_3982_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7db4/5473923/a8ce585f0e19/41598_2017_3982_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7db4/5473923/c07e7515c9c6/41598_2017_3982_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/7db4/5473923/8f64f58fe3ad/41598_2017_3982_Fig6_HTML.jpg

相似文献

1
Bovine antibodies targeting primary and recurrent Clostridium difficile disease are a potent antibiotic alternative.针对原发性和复发性艰难梭菌病的牛抗体是一种有效的抗生素替代药物。
Sci Rep. 2017 Jun 16;7(1):3665. doi: 10.1038/s41598-017-03982-5.
2
Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection.高免疫牛初乳作为一种对抗艰难梭菌感染的新型疗法。
J Infect Dis. 2015 Apr 15;211(8):1334-41. doi: 10.1093/infdis/jiu605. Epub 2014 Nov 7.
3
Mechanisms of protection against Clostridium difficile infection by the monoclonal antitoxin antibodies actoxumab and bezlotoxumab.单克隆抗毒素抗体actoxumab和bezlotoxumab预防艰难梭菌感染的机制。
Infect Immun. 2015 Feb;83(2):822-31. doi: 10.1128/IAI.02897-14. Epub 2014 Dec 8.
4
Characterization of Chicken IgY Specific to R20291 Spores and the Effect of Oral Administration in Mouse Models of Initiation and Recurrent Disease.针对R20291芽孢的鸡IgY特性及其在疾病起始和复发小鼠模型中的口服给药效果
Front Cell Infect Microbiol. 2017 Aug 14;7:365. doi: 10.3389/fcimb.2017.00365. eCollection 2017.
5
Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.艰难梭菌感染啮齿动物模型中的疾病进展与消退以及抗毒素抗体和万古霉素的影响
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6471-6482. doi: 10.1128/AAC.00974-16. Print 2016 Nov.
6
Treatment and Prevention of Recurrent Clostridium difficile Infection with Functionalized Bovine Antibody-Enriched Whey in a Hamster Primary Infection Model.在仓鼠原发性感染模型中,用功能化牛抗体富集乳清治疗和预防复发性艰难梭菌感染。
Toxins (Basel). 2019 Feb 6;11(2):98. doi: 10.3390/toxins11020098.
7
Clostridium difficile chimeric toxin receptor binding domain vaccine induced protection against different strains in active and passive challenge models.艰难梭菌嵌合毒素受体结合域疫苗在主动和被动攻击模型中诱导了针对不同菌株的保护作用。
Vaccine. 2017 Jul 24;35(33):4079-4087. doi: 10.1016/j.vaccine.2017.06.062. Epub 2017 Jun 29.
8
Bezlotoxumab: A Novel Agent for the Prevention of Recurrent Clostridium difficile Infection.贝洛妥珠单抗:一种用于预防复发性艰难梭菌感染的新型药物。
Pharmacotherapy. 2017 Oct;37(10):1298-1308. doi: 10.1002/phar.1990. Epub 2017 Sep 12.
9
Deciphering the domain specificity of C. difficile toxin neutralizing antibodies.解析艰难梭菌毒素中和抗体的结构特异性。
Vaccine. 2019 Jun 27;37(29):3892-3901. doi: 10.1016/j.vaccine.2019.05.040. Epub 2019 May 20.
10
The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Infection.单克隆抗毒素抗体(Actoxumab-Bezlotoxumab)治疗有助于感染小鼠肠道微生物群的正常化。
Front Cell Infect Microbiol. 2016 Oct 4;6:119. doi: 10.3389/fcimb.2016.00119. eCollection 2016.

引用本文的文献

1
Fit-for-purpose heterodivalent single-domain antibody for gastrointestinal targeting of toxin B from Clostridium difficile.适用于胃肠道靶向艰难梭菌毒素 B 的异价单域抗体。
Protein Sci. 2024 Jul;33(7):e5035. doi: 10.1002/pro.5035.
2
New treatment approaches for infections: alternatives to antibiotics and fecal microbiota transplantation.感染的新治疗方法:抗生素和粪便微生物群移植的替代品。
Gut Microbes. 2024 Jan-Dec;16(1):2337312. doi: 10.1080/19490976.2024.2337312. Epub 2024 Apr 9.
3
Immunization Strategies Against Clostridioides difficile.

本文引用的文献

1
Bezlotoxumab for Prevention of Recurrent Clostridium difficile Infection.贝洛妥珠单抗预防复发性艰难梭菌感染。
N Engl J Med. 2017 Jan 26;376(4):305-317. doi: 10.1056/NEJMoa1602615.
2
The Monoclonal Antitoxin Antibodies (Actoxumab-Bezlotoxumab) Treatment Facilitates Normalization of the Gut Microbiota of Mice with Infection.单克隆抗毒素抗体(Actoxumab-Bezlotoxumab)治疗有助于感染小鼠肠道微生物群的正常化。
Front Cell Infect Microbiol. 2016 Oct 4;6:119. doi: 10.3389/fcimb.2016.00119. eCollection 2016.
3
Disease Progression and Resolution in Rodent Models of Clostridium difficile Infection and Impact of Antitoxin Antibodies and Vancomycin.
针对艰难梭菌的免疫策略。
Adv Exp Med Biol. 2024;1435:117-150. doi: 10.1007/978-3-031-42108-2_7.
4
Bioactivity and efficacy of a hyperimmune bovine colostrum product- Travelan, against shigellosis in a non-Human primate model (Macaca mulatta).一种高免牛初乳产品-Travelan 对非人类灵长类动物模型(猕猴)中志贺氏菌病的生物活性和疗效。
PLoS One. 2023 Dec 13;18(12):e0294021. doi: 10.1371/journal.pone.0294021. eCollection 2023.
5
Hyperimmune bovine colostrum containing lipopolysaccharide antibodies (IMM124-E) has a nondetrimental effect on gut microbial communities in unchallenged mice.含有脂多糖抗体的高免牛初乳(IMM124-E)对未受挑战的小鼠肠道微生物群落没有不良影响。
Infect Immun. 2023 Nov 16;91(11):e0009723. doi: 10.1128/iai.00097-23. Epub 2023 Oct 13.
6
Application of recombinant antibodies for treatment of infection: Current status and future perspective.重组抗体在 感染治疗中的应用:现状与展望。
Front Immunol. 2022 Aug 23;13:972930. doi: 10.3389/fimmu.2022.972930. eCollection 2022.
7
Cationic Peptidomimetic Amphiphiles Having a -Aryl- or -Naphthyl-1,2,3-Triazole Core Structure Targeting () : Synthesis, Antibacterial Evaluation, and an In Vivo Infection Model.具有靶向()的 - 芳基 - 或 - 萘基 - 1,2,3 - 三唑核心结构的阳离子拟肽两亲物:合成、抗菌评估及体内感染模型
Antibiotics (Basel). 2021 Jul 26;10(8):913. doi: 10.3390/antibiotics10080913.
8
Alteration of Intestinal Microbiome of Infected Hamsters during the Treatment with Specific Cow Antibodies.感染仓鼠在接受特定牛抗体治疗期间肠道微生物群的改变
Antibiotics (Basel). 2021 Jun 16;10(6):724. doi: 10.3390/antibiotics10060724.
9
Bovine Colostrum: Its Constituents and Uses.牛初乳:成分与用途。
Nutrients. 2021 Jan 18;13(1):265. doi: 10.3390/nu13010265.
10
Anti-virulence strategies for infection: advances and roadblocks.抗感染的抗毒力策略:进展与障碍。
Gut Microbes. 2020 Nov 9;12(1):1802865. doi: 10.1080/19490976.2020.1802865.
艰难梭菌感染啮齿动物模型中的疾病进展与消退以及抗毒素抗体和万古霉素的影响
Antimicrob Agents Chemother. 2016 Oct 21;60(11):6471-6482. doi: 10.1128/AAC.00974-16. Print 2016 Nov.
4
CdtR Regulates TcdA and TcdB Production in Clostridium difficile.CdtR调节艰难梭菌中TcdA和TcdB的产生。
PLoS Pathog. 2016 Jul 14;12(7):e1005758. doi: 10.1371/journal.ppat.1005758. eCollection 2016 Jul.
5
Clostridium difficile infection.艰难梭菌感染。
Nat Rev Dis Primers. 2016 Apr 7;2:16020. doi: 10.1038/nrdp.2016.20.
6
The Role of Rho GTPases in Toxicity of Clostridium difficile Toxins.Rho GTP酶在艰难梭菌毒素毒性中的作用
Toxins (Basel). 2015 Dec 2;7(12):5254-67. doi: 10.3390/toxins7124874.
7
Defining the Roles of TcdA and TcdB in Localized Gastrointestinal Disease, Systemic Organ Damage, and the Host Response during Clostridium difficile Infections.确定艰难梭菌感染期间TcdA和TcdB在局部胃肠道疾病、全身器官损伤及宿主反应中的作用。
mBio. 2015 Jun 2;6(3):e00551. doi: 10.1128/mBio.00551-15.
8
Emergence of toxin A-negative, toxin B-positive Clostridium difficile strains: epidemiological and clinical considerations.毒素A阴性、毒素B阳性艰难梭菌菌株的出现:流行病学和临床考量
Future Microbiol. 2015;10(1):1-4. doi: 10.2217/fmb.14.115.
9
Clostridium difficile virulence factors: Insights into an anaerobic spore-forming pathogen.艰难梭菌毒力因子:一种厌氧芽孢形成病原体的深入了解。
Gut Microbes. 2014;5(5):579-93. doi: 10.4161/19490976.2014.969632.
10
Hyperimmune bovine colostrum as a novel therapy to combat Clostridium difficile infection.高免疫牛初乳作为一种对抗艰难梭菌感染的新型疗法。
J Infect Dis. 2015 Apr 15;211(8):1334-41. doi: 10.1093/infdis/jiu605. Epub 2014 Nov 7.